Dupilumab suppression of Th2 biomarkers correlates with reduction in transepidermal water loss (TEWL) and clinical improvements in adults with moderate-to-severe atopic dermatitis (AD)

被引：0
|
作者：
Hamilton, J. [1 ]
Hamon, S. [1 ]
Chaudhry, U. [1 ]
Simpson, E. L. [2 ]
Swanson, B. [3 ]
Liu, M. [4 ]
Ren, H. [4 ]
Graham, N. [1 ]
Pirozzi, G. [3 ]
Ardeleanu, M. [1 ]
机构：
[1] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[2] Oregon Hlth & Sci Univ, Portland, OR USA
[3] Sanofi, Bridgewater, NJ USA
[4] Regeneron Pharmaceut Inc, Basking Ridge, NJ USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2015年 / 135卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
169
引用
收藏
页码：S29 / S29
页数：1
相关论文
共 50 条
  • [1] Dupilumab treatment restores skin barrier function measured by transepidermal water loss in adults and adolescents with moderate-to-severe atopic dermatitis
    Bissonnette, R.
    Ramirez-Gama, M.
    Garcia, S.
    Taylor, P.
    Praestgaard, A.
    Levit, N. A.
    Rossi, A. B.
    Zhang, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E156 - E156
  • [2] Dupilumab elicits rapid and sustained improvements in itch in adults with moderate-to-severe atopic dermatitis
    Silverberg, J. I.
    Eckert, L.
    Yosipovitch, G.
    Kim, B.
    Simpson, E. L.
    Rossi, A. B.
    Ardeleanu, M.
    Chen, Z.
    Kaur, M.
    Gadkari, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S105 - S105
  • [3] The effect of dupilumab on biomarkers in a randomized phase 2b clinical trial in adults with moderate-to-severe atopic dermatitis
    Hamilton, J.
    Hamon, S.
    Simpson, E.
    Chaudhry, U.
    Swanson, B.
    Zhang, R.
    Graham, N.
    Pirozzi, G.
    Ardeleanu, M.
    Rizova, E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (09) : S224 - S224
  • [4] Baseline serum biomarkers do not predict dupilumab treatment response in adults with moderate-to-severe atopic dermatitis
    Weidinger, Stephan
    Beck, Lisa A.
    de Bruin-Weller, Marjolein S.
    Thyssen, Jacob P.
    Kabashima, Kenji
    Guttman-Yassky, Emma
    Akdis, Cezmi A.
    Chen, Zhen
    Levit, Noah A.
    Bastian, Mike
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [5] Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials
    Katoh, N.
    Kataoka, Y.
    Saeki, H.
    Hide, M.
    Kabashima, K.
    Etoh, T.
    Igarashi, A.
    Imafuku, S.
    Kawashima, M.
    Ohtsuki, M.
    Fujita, H.
    Arima, K.
    Takagi, H.
    Chen, Z.
    Shumel, B.
    Ardeleanu, M.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (01) : 39 - 51
  • [6] Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis A Randomized Clinical Trial
    Blauvelt, Andrew
    Teixeira, Henrique D.
    Simpson, Eric L.
    Costanzo, Antonio
    De Bruin-Weller, Marjolein
    Barbarot, Sebastien
    Prajapati, Vimal H.
    Lio, Peter
    Hu, Xiaofei
    Wu, Tianshuang
    Liu, John
    Ladizinski, Barry
    Chu, Alvina D.
    Eyerich, Kilian
    JAMA DERMATOLOGY, 2021, 157 (09) : 1047 - 1055
  • [7] Vascular inflammation in moderate-to-severe atopic dermatitis is associated with enhanced Th2 response
    Villani, Axel P.
    Pavel, Ana B.
    Wu, Jianni
    Fernandes, Marie
    Maari, Catherine
    Proulx, Etienne Saint-Cyr
    Jack, Carolyn
    Glickman, Jacob
    Choi, Seulah
    He, Helen
    Ungar, Benjamin
    Estrada, Yeriel
    Kameyama, Naoya
    Zhang, Ning
    Gonzales, Juana
    Tardif, Jean-Claude
    Krueger, James G.
    Bissonnette, Robert
    Guttman-Yassky, Emma
    ALLERGY, 2021, 76 (10) : 3107 - 3121
  • [8] The patient burden of atopic dermatitis: insights from a dupilumab phase 2 clinical trial in adults with moderate-to-severe disease
    Mastey, V.
    Simpson, E.
    Bieber, T.
    Eckert, L.
    Wu, R.
    Ardeleanu, M.
    Graham, N.
    Pirozzi, G.
    Sutherland, E. R.
    EXPERIMENTAL DERMATOLOGY, 2014, 23 : 4 - 4
  • [9] Dupilumab provides clinically meaningful responses in adults with moderate-to-severe atopic dermatitis (AD): Results from LIBERTY AD CHRONOS study
    Silverberg, Jonathan I.
    Simpson, Eric L.
    de Bruin-Weller, Marjolein
    Foley, Peter
    Kataoka, Yoko
    Chen, Zhen
    Shumel, Brad
    Rossi, Ana B.
    Sierka, Debra
    Chao, Jingdong
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB152 - AB152
  • [10] Dupilumab provides clinically meaningful responses in adults with moderate-to-severe atopic dermatitis (AD): Results from LIBERTY AD CHRONOS study
    Silverberg, J., I
    Simpson, E. L.
    Bieber, T.
    de Bruin-Weller, M.
    Foley, P.
    Kataoka, Y.
    Bastian, M.
    Chen, Z.
    Levit, N. A.
    Rossi, A. B.
    Sierka, D.
    Chao, J.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 61 - 61
12345